In this article, we will take a detailed look at 10 Stocks Insiders Are Buying This Year. We previously covered Why These 15 Software Stocks Are Skyrocketing So Far in 2025.
Even though this is just the beginning of the year, we thought it might be interesting to see what stocks have attracted the most attention from insiders. Why? Sometimes, when executives or insiders acquire shares early in the year, it could mean that they expect strong financial results or positive company developments.
On the other hand, insiders sometimes sell shares at the beginning of the year for tax reasons. For example, they can sell shares to harvest tax loss or to balance out gains/losses from the previous year.
Both insider selling and buying can be driven by various motives, however, it’s important to consider these moves within the broader context of the company’s fundamentals, industry trends, and overall market conditions. That’s why due diligence before any investment is of the utmost importance. However, insider trading activity in combination with other relevant determinants can offer valuable insights into a company’s capabilities, helping investors make more informed investment decisions.
To identify the 10 stocks insiders are buying this year we used Insider Monkey’s insider trading stock screener and looked for stocks with at least five insiders buying since the beginning of the year. With each stock, we note the number of insiders who recently bought shares.
Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here)
A young professional in a suit and tie making a call from a smartphone in a crowded trading floor.
10. Flowco Holdings Inc. (NYSE:FLOC)
Number of Insiders Buying: 6
We start our list with the 10th stock insiders have been buying in 2025 – Flowco Holdings. This is a provider of production optimization and methane mitigation solutions for exploration and production (E&P) operators. The company operates in two segments: Production Solutions and Natural Gas Technologies. It offers rent, service, and sale of high-pressure gas lifts, conventional gas lifts, and plunger lifts.
On January 17, six insiders, including the President and CEO, and CFO, bought a total of approximately $1.89 million worth of Flowco shares at a price of $24 per share. Out of that amount, the company’s CEO, R Joseph Edwards, purchased 50,000 shares, worth $1.2 million, increasing his holding to 184,792 shares. The company was founded in 2024, and it went public in January 2025, so these purchases were a part of the company’s initial public offering.
Four analysts have an average “Strong Buy” rating on the stock, with a 12-month stock price target of $33.5. The current price target represents an increase of 27.38% from the latest price, according to data from StockAnalysis.
Since it is a newly listed company, the company hasn’t disclosed detailed financial results.
Since the beginning of the year, Flowco’s share price dropped 11.45%, and is currently trading at $26.30.
With a market cap of $2.38 billion, this is also one of the 10 Mid-Cap Stocks Insiders Are Buying Recently.
9. Sionna Therapeutics Inc. (NASDAQ:SION)
Number of Insiders Buying: 6
Sionna Therapeutics is a biopharmaceutical company developing treatments for cystic fibrosis (CF). The company is focused on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Its goal is to create various medicines for people with CF that will restore CFTR function to nearly normal.
The company’s co-founders have more than a decade of research in this area, so Sionna is working on advancing a pipeline of small molecules engineered to correct the defects caused by the most common CF genetic mutation.
On February 10th, six insiders acquired $62.46 million worth of Sionna shares at a price of $18 per share. Insiders took part in the company’s upsized initial public offering, via which it raised $219.2 million. Sionna said it plans to use raised capital to advance its CF drug development programs.
Director Peter A. Thompson showed confidence in the company’s future by buying 550,000 shares, worth $9.9 million. With this move, Thompson raised his holding to 3.70 million Sionna’s shares.
Since this is a stock that recently went public, there’s not much analyst coverage yet, and also no public finance reports.
The stock is currently trading at $20.03, and its market cap is $849.29 million.